Dyslipidemia in the Russian Federation: population data, associations with risk factors

Aim. To study the prevalence of dyslipidemias and their association with various risk factors in the Russian population of men and women aged 35-74 years in 2020-2022.

Material and methods. This work was carried out as part of the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation-3 (ESSE-RF3) study. The sample included 28731 men and women aged 35-74 years living in 15 Russian regions. Hypercholesterolemia (HC) was diagnosed with total cholesterol (TC) ≥5,0 mmol/l, while elevated low-density lipoprotein cholesterol (LDL-C) was considered ≥3,0 mmol/l, hypertriglyceridemia — with triglyceride levels ≥1,7 mmol/l, reduced high-density lipoprotein cholesterol (HDL-C) <1,0 mmol/l in men and <1,2 mmol/l in women. Associations were assessed using logistic regression after adjustment for socio-demographic characteristics, drinking status, presence of hypertension (HTN) and stroke.

Results. The prevalence of hypertriglyceridemia in the Russian Federation in 2020-2022 was 58,8%, hypertriglyceridemia — 32,2%. The incidence of lipid-lowering therapy increased with age from 1% in the group of 35-44 years to 16% in the group of 65-74 years. On average, only 7,6% of study participants received lipid-lowering therapy. Significant associations of HC with HTN, obesity and alcohol abuse were identified. Similar results were obtained for elevated LDL-C levels, with the exception of alcohol abuse. In turn, a reduced HDL-C level was significantly associated with the lack of higher education, marriage, physical activity, smoking and the presence of diseases.

Conclusion. The prevalence of lipid disorders in the Russian Federation in 2020-2022 remained at a high level. These disorders occurred more often in women, and they were better informed about their cholesterol levels and more often received lipid-lowering therapy. HTN, obesity, and some behavioral and social risk factors were associated with dyslipidemia.

1. Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):139-48.

2. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56. doi:10.1038/s41572-019-0106-z.

3. Institute for Health Metrics and Evaluation. Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME. 2018;1-25.

4. Kontsevaya AV, Balanova YuA, Imaeva AE, et al. Economic burden of hypercholesterolemia in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2018;14(3):393-401. (In Russ.) doi:10.20996/1819-6446-2018-14-3-393-401.

5. NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582:73-7. doi:10.1038/s41586-020-2338-1.

6. Vancheri F, Backlund L, Strender LE, et al. Time trends in statin utilisation and coronary mortality in Western European countries. BMJ Open. 2016;6:e010500. doi:10.1136/bmjopen-2015-010500.

7. Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Archives of medical research. 2015;46(5):328-38. doi:10.1016/j.arcmed.2015.06.006.

8. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563-95. doi:10.1161/CIR.0000000000000677.

9. Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375(24):2349-58. doi:10.1056/NEJMoa1605086.

10. Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: results of the ESSE-RF study for the years 2012-2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7. (In Russ.) doi:10.15829/1728-8800-2017-4-62-67.

11. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina. 2016;19(1):15‑23. (In Russ.) doi:10.17116/profmed201619115-23.

12. Drapkina OM, Shalnova SA, Imaeva AE, et al. Epidemiology of Cardiovascular Diseases in Regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Cardiovascular Therapy and Prevention. 2022;21(5):3246. (In Russ.) doi:10.15829/1728-8800-2022-3246.

13. Imaeva AE, Tuaeva EM, Shalnova SA, et al. Coronary heart disease and risk factors in elderly population. Cardiovascular Therapy and Prevention. 2016;15(2):93-9. (In Russ.) doi:10.15829/1728-8800-2016-2-93-99.

14. Li Z, Zhu G, Chen G, et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. Lipids Health Dis. 2022;21(1):111. doi:10.1186/s12944-022-01721-y.

15. Wang M, Liu M, Li F, et al. Gender heterogeneity in dyslipidemia prevalence, trends with age and associated factors in middle age rural Chinese. Lipids Health Dis. 2020;19(1):135. doi:10.1186/s12944-020-01313-8.

16. Lizcano F, Guzmán G. Estrogen Deficiency and the Origin of Obesity during Menopause. Biomed Res Int. 2014;2014:757461. doi:10.1155/2014/757461.

17. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25(4):563-77. vii. doi:10.1016/j.cger.2009.07.007.

18. Martone AM, Landi F, Petricca L, et al. Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project. Eur J Public Health. 2022;32(3):402-7. doi:10.1093/eurpub/ckab224.

19. Vartiainen E, Laatikainen T, Tapanainen H, et al. Changes in Serum Cholesterol and Diet in North Karelia and All Finland. Global Heart. 2016;11:179-84. doi:10.1016/j.gheart.2016.04.006.

20. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. doi:10.1016/S0140-6736(04)17018-9.

21. Karamnova NS, Rytova AI, Shvabskaya OB. Associations of eating and drinking habits with cardiovascular disease and diabetes in the adult population: data from the ESSE-RF epidemiological study. Cardiovascular Therapy and Prevention. 2021;20(5):2982. (In Russ.) doi:10.15829/1728-8800-2021-2982.

22. Shalnova SA, Deev AD. High-risk patient characteristics. Results of the OSCAR Study: epidemiological part. Cardiovascular Therapy and Prevention. 2006;5(5):58-63. (In Russ.)

23. Rudkowska I, Jones PJ. Functional foods for the prevention and treatment of cardiovascular diseases: cholesterol and beyond. Expert Rev Cardiovasc Ther. 2007;5(3):477-90. doi:10.1586/14779072.5.3.477.

24. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. doi:10.1001/jama.2009.1619.

25. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-23. doi:10.1016/S0140-6736(10)60834-3.

26. Manjunath CN, Rawal JR, Irani PM, et al. Atherogenic dyslipidemia. Indian J Endocrinol Metab. 2013;17(6):969-76. doi:10.4103/2230-8210.122600.

27. Chen S, Cheng W. Relationship between lipid profiles and hypertension: a cross-sectional study of 62,957 Chinese adult males. Front Public Health. 2022;10:895499. doi:10.3389/fpubh.2022.895499.

28. Otsuka T, Takada H, Nishiyama Y, et al. Dyslipidemia and the risk of developing hypertension in a working-age male population. J Am Heart Assoc. 2016;5(3):e003053. doi:10.1161/JAHA.115.003053.

29. Zhu J, Zhang Y, Wu Y, et al. Obesity and dyslipidemia in Chinese adults: a cross-sectional study in Shanghai, China. Nutrients. 2022;14(11):2321. doi:10.3390/nu14112321.

30. Stefanović A, Zeljković A, Vekić J, et al. Dyslipidemia in type 2 diabetes mellitus. Arhiv Za Farmaciju. 2019;69(5):338-48. doi:10.5937/arhfarm1905338s.

31. George S, John S, George S, et al. Lipid profile and alcoholism. Int J Adv Med. 2019;6(5):1-8. doi:10.18203/2349-3933.ijam20193595.

32. Kim SK, Kim HC, Shim JS, et al. Effects of cigarette smoking on blood lipids in Korean men: Cardiovascular and Metabolic Diseases Etiology Research Center cohort. Korean J Intern Med. 2020;35(2):369-82. doi:10.3904/kjim.2019.133.

33. Colsoul M-L, Goderniaux N, Onorati S, et al. Changes in biomarkers of endothelial function, oxidative stress, inflammation and lipids after smoking cessation: A cohort study. Eur J Clin Invest. 2023;53:e013996. doi:10.1111/eci.13996.

34. Kodama S, Tanaka S, Saito K, et al. Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol: A Meta-analysis. Arch Intern Med. 2007;167(10):999-1008. doi:10.1001/archinte.167.10.999.

35. Crichton GE, Alkerwi A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. Lipids Health Dis. 2015;14:87. doi: 10.1186/s12944-015-0085-3.

36. Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis. 2017;16(1):132. doi:10.1186/s12944-017-0515-5.

37. Woo J, Leung S, Ho S, et al. Influence of educational level and marital status on dietary intake, obesity and other cardiovascular risk factors in a Hong Kong Chinese population. Eur J Clin Nutr. 1999;53:461-7. doi:10.1038/sj.ejcn.160077.